Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...
  •  
Login | Create an Account

2019 Practical Application of New Agents in Oncology Pharmacy CPE


Welcome to the Practical Applications for New Agents in Oncology (PANAO) Pharmacy CPE Evaluation Site for Pharamcy CPE credit. 
  • Complete the registration, and then complete the evaluations for each session you attended.
  • Your CPE Credits will be loaded to your NABP Profile once the evaluations are completed.
 

Date: Feb 1, 2019 04:30 PM - Feb 2, 2019 04:15 PM

Fee

$0.00

CE Hours

10.75

CE Units

1.075

Registration closes on Mar 31, 2019 01:00 AM

Activity Type

  • Knowledge

Target Audience(s)

  • Pharmacists

Accreditation(s)

“This statement contains information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit.  The official record of credit may be located in the learner’s e-profile in CPE Monitor®.”
Accreditation Council for Pharmacy Education
The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
 

Co-Sponsor(s)

San Antonio Breast Cancer Symposium • UT Health San Antonio

Requirements for CE Credit

The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This knowledge-based activity has been accredited for 01.075 total CEUs or (10.75) contact hours.  Successful completion of the program includes attending the accredited session(s) and completing an online evaluation(s).  Note, individuals are only eligible to receive up to 8.75 contact hours of credit due to concurrent scheduled sessions. 
 

 

 

Registration closes on Mar 31, 2019 at 01:00 AM

Registration Closed  

Matthew Butler, MD
UT Health San Antonio, Mays Cancer Center
San Antonio, TX
 
Learning Objectives:
  • Discuss induction therapy alternatives to VRd  - KRd  - Front-line daratumumab-based regimens  
  • Describe consolidation therapy: eternal questions about the role of transplant  - KRd/ASCT versus KRd12 (FORTE trial)   
  • Discuss maintenance therapy: alternatives to lenalidomide  - ixazomib after ASCT (TOURMALINE-MM3 trial)  - Rd-R versus indefinite Rd in "intermediate fit" patients   
  • Discuss High-risk smoldering myeloma treatments: eternal questions about whether to treat

Activity Number

0067-9999-19-006-L01-P
Date: 02/01/19
Time: 05:30 PM - 06:10 PM

CE Hours

0.75
Registration Closed  

Registration Closed  

Robert Orlowski, MD, PhD
MD Anderson Cancer Center
Houston, TX
 
  • Discuss the latest treatment updates regarding relapse and refractory multiple myeloma

Speaker(s)/Author(s)

Robert Orlowski, MD, PhD
MD Anderson Cancer Center

Activity Number

0067-9999-19-007-L01-P
Date: 02/01/19
Time: 06:10 PM - 06:50 PM

CE Hours

0.75
Registration Closed  

Registration Closed  

Virginia Kaklamani, MD, DSc
UT Health San Antonio, Mays Cancer Center
San Antonio, TX
  • Discuss the role of immunotherapy in breast cancer, updates on HER2 positive breast cancer, and novel drug therapies for er+ breast cancer.

Activity Number

0067-9999-19-008-L04-P
Date: 02/01/19
Time: 06:50 PM - 07:30 PM

CE Hours

0.75
Registration Closed  

Registration closes on Mar 31, 2019 at 01:00 AM

Registration Closed  

Georgia McCann, MD
UT Health San Antonio, Mays Cancer Center
San Antonio, TX
 
  • Describe options for maintenance therapy in the front-line treatment of ovarian cancer.
  • Describe the role of checkpoint inhibitors in the treatment of recurrent endometrial and cervical cancer.

Activity Number

0067-9999-19-014-L03-P
Date: 02/02/19
Time: 08:00 AM - 08:40 AM

CE Hours

0.75
Registration Closed  

Registration Closed  

Timothy Yap, MBBS, PhD, MRCP (UK), BSc (Hons), PgDip
MD Anderson Cancer Center
Houston, TX
  • Discuss successes with biomarker-driven therapeutics including limitations with precision medicine.
  • Discuss the MD Anderson Cancer Center (MDACC) Clearinghouse study with a focus on issues identified with precision medicine and steps implemented at MDACC    
  • Discuss current and future priorities in precision medicine

Activity Number

0067-9999-19-047-L04-P
Date: 02/02/19
Time: 08:40 AM - 09:20 AM

CE Hours

0.75
Registration Closed  

Registration Closed  

Tyler Curiel, MD
UT Health San Antonio, Mays Cancer Center
San Antonio, TX
  • Describe the gaps of current Checkpoint inhibition
  • Discuss the science behind additional approaches and what trials are ongoing/results to test

Activity Number

0067-9999-19-011-L04-P
Date: 02/02/19
Time: 09:20 AM - 10:00 AM

CE Hours

0.75
Registration Closed  

Registration Closed  

Track 1: Concurrent Session I
 
Robyn Scherber, MD, MPH
UT Health San Antonio, Mays Cancer Center
San Antonio, TX
  • Discuss use of new investigational agents in care of MDS and MPN patients  with an overview the state of the field in terms of treatment and the current standards of care in MDS & MPN.  
  • List novel strategies to ease the treatment challenges for MDS & MPN patients. 
  • Describe some of the integrative and non-traditional treatment strategies being pursued in MDS & MPN.

Activity Number

0067-9999-19-048-L04-P
Date: 02/02/19
Time: 10:30 AM - 11:00 AM

CE Hours

0.50
Registration Closed  

Registration Closed  

Track 1: Concurrent Session II
 
Naveen Pemmaraju, MD – changed speaker
MD Anderson Cancer Center
Houston, TX
  • Describe the clinical progress in the field of MDS in terms of subgoups of pre-cursor disease and low, int, high risk MDS. –
  • Describe novel therapy options (on and off clinical trials) to provide discussion for latest treatments in MDS.

Activity Number

0067-9999-19-013-L04-P
Date: 02/02/19
Time: 11:00 AM - 11:30 AM

CE Hours

0.50
Registration Closed  

Registration Closed  

Track 1: Concurrent Session III

Elizabeth Bowhay-Carnes, MD

UT Health San Antonio, Mays Cancer Center

San Antonio, TX

 

·       Review the recommendations set forth in the American Society of Hematology 2018 guidelines for management of venous thromboembolism.

·       Review FDA approved medications for treatment of various benign hematologic conditions.

Activity Number

0067-9999-19-010-L04-P
Date: 02/02/19
Time: 11:30 AM - 12:00 PM

CE Hours

0.50
Registration Closed  

Registration Closed  

Track 2: Concurrent Session I
 
Jeffrey Betcher, RPh, BCOP
Mayo Clinic
Phoenix, AZ
 
  • Define what constitutes a biosimilar product and the road to approval
  • List the currently FDA-approve biosimilars for cancer diagnoses
  • Identify key barriers to biosimilars coming to market
  • Describe strategies for healthcare teams to successfully integrate bio-similar medications into practice

Activity Number

0067-9999-19-009-L04-P
Date: 02/02/19
Time: 10:30 AM - 11:00 AM

CE Hours

0.50
Registration Closed  

Registration Closed  

Track 2 - Concurrent Session II
 
Laura Tenner, MD, MPH
UT Health San Antonio, Mays Cancer Center
San Antonio, TX
 
  • Define Patient Reported Outcomes
  • Discuss how Patient Reported Outcomes have been integrated in Cancer Care

Activity Number

0067-9999-19-049-L04-P
Date: 02/02/19
Time: 11:00 AM - 11:30 AM

CE Hours

0.50
Registration Closed  

Registration Closed  

Track 2 - Concurrent Session III
 
Jeremy Viles, DNP, MBA, RN, Ne-BC
UT Health San Antonio, Mays Cancer Center
San Antonio, TX
 
  • Discuss effective strategies for patient-and family-centered oncology care in a modern oncology practice
  • Identify and discuss modern practices to better incorporate patient-and family-centered care into their practice environment.

Activity Number

0067-9999-19-050-L04-P
Date: 02/02/19
Time: 11:30 AM - 12:00 PM

CE Hours

0.50
Registration Closed  

Registration Closed  

Katherine Mishaw, MS, RN-BC, OCN, AOCN
MD Anderson Cancer Center
Houston, TX
  • Describe the novel mechanism of actions of the Immune checkpoint inhibitors.
  • Discuss the prevention and surveillance for immune related side effects of these novel agents.
  • Identify the nursing and medical management of patients experiencing side effects of Checkpoint inhibitors

Activity Number

0067-9999-19-015-L04-P
Date: 02/02/19
Time: 01:00 PM - 01:40 PM

CE Hours

0.75
Registration Closed  

Registration Closed  

Tonya Edwards, MS, MSN, RN, FNP-C
MD Anderson Cancer Center
Houston, TX
  • Discuss new guidelines with pain control and safe prescribing, including non-adherence with opioid Therapy
  • Discuss strategic management planning for opioid therapy
  • Discuss new mandates with Pharmacy Drug Monitoring Describe Program

Activity Number

0067-9999-19-012-L04-P
Date: 02/02/19
Time: 01:40 PM - 02:20 PM

CE Hours

0.75
Registration Closed  

Registration Closed  

Chethan Ramamurthy, MD
UT Health San Antonio, Mays Cancer Center
San Antonio, TX
  • Describe front line treatment options for metastatic renal cell carcinoma.
  • Describe toxicity profiles of the various treatment options for metastatic renal cell carcinoma.

Activity Number

0067-9999-19-016-L04-P
Date: 02/02/19
Time: 02:30 PM - 03:10 PM

CE Hours

0.50
Registration Closed  

Registration Closed  

Ramesh Ramanathan, MD
Merck Research Laboratories
Phoenix, AZ
  • Discuss current status and limitations of immunotherapy in pancreatic cancer
  • Name new agents in the treatment of pancreatic cancer

Activity Number

0067-9999-19-017-L04-P
Date: 02/02/19
Time: 03:10 PM - 03:40 PM

CE Hours

0.75
Registration Closed  

Registration Closed  

John Sarantopoulos, MD
UT Health San Antonio, Mays Cancer Center
San Antonio, TX
 
  • Describe the pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected oncology drugs recently marketed as well as drugs approaching the market.

Activity Number

0067-9999-19-046-L04-P
Date: 02/02/19
Time: 03:40 PM - 04:15 PM

CE Hours

0.50
Registration Closed  



System Requirements
Please ensure the computer system you plan to use meets the following minimum requirements:
  • Operating System: Windows 7 or higher, macOS Sierra (10.12) or higher
  • Internet Browser: Chrome 30 or higher, Firefox 27 or higher, Internet Explorer 11, Microsoft Edge, Safari 9 or higher
  • Internet connection: Cable, High-speed DSL, and any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones Media Viewing Requirements: Adobe Reader, HTML5
Education Disclaimer
The author(s) of this continuing education activity have made reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific evidence at the time of publication. However, because information regarding medications, treatment guidelines, and other healthcare information is subject to constant change, the participant is advised to always confirm practice resources before applying any learned information in practice.Activities produced by UT Continuing Pharmacy Education are intended solely for purposes of supplementing health care professionals’ knowledge. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of The University of Texas at Austin College of Pharmacy.
 
The University of Texas at Austin College of Pharmacy • Continuing Pharmacy Education
2409 University Ave., Stop A1904 | Austin, Texas 78712
Comments to:  UTpharmacyCE@austin.utexas.edu
College of Pharmacy, The University of Texas at Austin
 
LMS Powered By: Learning ExpressCE
Copyright © 2024 University of Texas at Austin College of Pharmacy. All Rights Reserved.
About Us Privacy Policy Terms of Service